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ABSTRACT
Crohn’s disease (CD) is rapidly increasing in children so
an up to date knowledge of diagnosis, investigation and
management is essential. Exclusive enteral nutrition is
the ﬁrst line treatment for active disease. The vast
majority of children will need immunosuppressant
treatment and around 20% will need treatment with
biologics. Recent guidelines have helped make best use
of available therapies.
INTRODUCTION
Crohn’s disease (CD) is a chronic inﬂammatory dis-
order, which can affect any part of the intestinal
tract as well as extraintestinal tissue. Factors that
contribute towards the pathogenesis of the disease
are the host’s genetic proﬁle, immune system and
environmental factors such as the gut microbiota.1
CD occurs in all ages with recently reported
paediatric ﬁgures from Scotland and South England
suggesting an incidence of 4.75 and 5.85/100 000
people, respectively.2 3 UK prevalence data are
limited, but suggest a ﬁgure of 32 per 100 000
people.4 Due to yet undeﬁned environmental
factors, the incidence and prevalence of CD is
rising, in both adult and paediatric studies.5 6
In this review, we aimed to update important
new developments in the management of CD for
paediatricians in the UK highlighting the key publi-
cations and guidelines published recently.7 We also
recognise that the BSPGHAN inﬂammatory bowel
disease (IBD) guidelines published previously, now
contain many recommendations that needed
updated guidance, but without generation of a
speciﬁcally new guideline.8 9
Diagnosis
Key clinical symptoms of CD comprise diarrhoea,
abdominal pain, growth failure and rectal bleeding
with the ﬁrst three being the most common in
patients ﬁrst presenting with CD.10 CD often has
an insidious onset, which may contribute to consid-
erable diagnostic delay. CD can affect the entire
intestinal tract, and transmural inﬂammation can
lead to stricture formation and ﬁstulisation between
the gut and other abdominal organs as well as the
skin.11 Perianal inspection is imperative as signiﬁ-
cant perianal involvement (eg, inﬂamed ﬁssures or
skin tags, abscesses and ﬁstulae) are seen at presen-
tation in at least 15% of children with CD12 (see
ﬁgure 1). Extraintestinal manifestations in IBD can
affect the skin, eyes, musculoskeletal and hepato-
biliary systems.13
Once IBD is suspected, patients should be fast
tracked to specialist services (for relevant blood
and stool tests see Fell et al13a and ﬁgure 2). The
revised Porto criteria provide detailed guidance on
the diagnostic evaluation of paediatric patients with
IBD10 emphasising the necessity to perform upper
gastrointestinal endoscopy and ileocolonoscopy
with histology as well as small bowel imaging (see
ﬁgure 1).14
Once CD has been established, ongoing disease
activity is monitored by clinical review and assess-
ment. The originally reported Paediatric Crohn’s
Disease Activity Index (PCDAI)15 is now mostly
superseded by the weighted PCDAI which takes
clinical symptoms, laboratory markers, anthropo-
metric data and clinical examination into account
(table 1).16 This is an assessment, which can be
used by all paediatricians to objectively assess
disease activity.
TREATMENT STRATEGY
Treatment aims are to induce and maintain clinical
remission, optimise nutrition, deﬁne bone status,
optimise growth and pubertal progress and minim-
ise drug adverse effects. Treatment beyond simple
symptom resolution is now commonly employed
with intestinal/mucosal healing the target of con-
temporary CD care.17
The strategy of early introduction of immunomo-
dulatory and biological therapies to induce deep
remission (long-term intestinal healing without
relapse) particularly in high-risk patients (severe
endoscopic or perianal disease, poor response to
induction therapy, extensive, stricturing or pene-
trating disease, marked growth retardation and/or
severe osteoporosis) might change the natural
history of the disease and is being increasingly used
in paediatric IBD.
INDUCTION OF REMISSION
Exclusive enteral nutrition
Exclusive enteral nutrition (EEN) for 6–8 weeks,
using a whole protein formula is the ﬁrst-line
therapy to induce remission in children with active
CD.7 Clinical response rates are approximately
80% and similar to corticosteroids.18 19 However,
in contrast to corticosteroids, EEN offers signiﬁcant
nutritional advantages and provides superior
mucosal healing in comparison to steroids.20 21
Clinical improvement usually occurs within days
and alternative therapy should be considered in the
absence of response within 2–4 weeks. No differ-
ences between polymeric (whole protein) and
elemental (amino acid) formulae have been
shown.22 23 Polymeric feeds are the preferred
option as they are better tolerated, more cost-
effective and require less nasogastric feeding.24
Success with EEN is maximised by robust and
frequent patient and family support from the multi-
disciplinary team (MDT), particularly in the early
stages of treatment. Clinical review halfway
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through therapy further facilitates completion of the full
course.25 Limited data suggest that ongoing maintenance enteral
nutrition can be a useful strategy in some children after the
course of exclusive enteral nutrition is complete.26
Corticosteroids
Corticosteroids can be used to induce remission in CD, if EEN
is not possible or the patient does not respond to therapy.
Prednisolone is given orally (1 mg/kg, maximum: 40 mg/day,
tapering over 8–10 weeks) for moderate/severe active luminal
CD. For mild/moderate ileocaecal disease, budesonide is an
alternative option with fewer steroid-related side effects
(maximum: 12 mg/day, tapering over 2–4 weeks). Intravenous
steroids (preferred intravenous steroid: methylprednisolone at
1–1.5 mg/kg, maximum: 60 mg/day; or alternatively: hydrocor-
tisone 2–4 mg/kg/dose, maximum 100 mg/dose four times a
day) may be initially needed for severe disease.
Similar to EEN, clinical remission rates of up to 80% have
been reported, but with considerably lower mucosal healing
rates.27 28 Adverse effects are proportional to dose and dur-
ation, and include adrenal suppression, growth failure, cosmetic
and behavioural effects.
Anti-tumour necrosis factor α antibodies
Anti-tumour necrosis factor (TNF) therapy is also recognised as
induction therapy for selected patients with moderate to severe
disease. These therapies will be discussed in detail in the
Maintenance of remission section.
Antibiotics
Adult studies demonstrating reduced ﬁstula drainage support the
use of antibiotics (metronidazole and/or ciproﬂoxacin) in
perianal ﬁstulising CD disease.29 Limited paediatric data on
combination treatment with azithromycin and metronidazole in
luminal disease have been encouraging, but await validation in
larger better designed clinical trials.30
MAINTENANCE OF REMISSION
Thiopurines
Results from paediatric and adult studies support the use of
thiopurines (6-mercaptopurine or azathioprine) to maintain
disease remission.27 31 At 18 months, cumulative steroid doses
and relapse rates were signiﬁcantly lower in children on
6-mercaptopurine compared with placebo (9% vs 47%). In
addition, a reduced need for surgery in CD was reported in
patients on azathioprine.32 These beneﬁts need to be balanced
against the side effects and long-term risks of immunosuppres-
sant therapy.33 For detailed management of azathioprine see Fell
et al.13a
Methotrexate
Paediatric retrospective cohort studies report 50%–80% effect-
iveness of methotrexate (MTX) in children who failed to
respond or were intolerant to thiopurine therapy in maintaining
remission.34 35
MTX (15 mg/m2 one time per week, maximum: 25 mg sub-
cutaneously) in conjunction with folate supplementation is an
alternative option as primary maintenance therapy or following
thiopurine failure or intolerance.7
MTX is particularly suitable as ﬁrst-line treatment in patients
who have coexistent inﬂammatory arthritis.36 Data on oral bio-
availability are variable, but the latest evidence suggests that ini-
tiating treatment subcutaneously followed by administering the
drug orally can be an alternative to long-term subcutaneous
administration.37 Adverse events include ﬂu-like symptoms,
transaminitis and infrequently myelosuppression, which may
require dosage adjustment or drug withdrawal. Signiﬁcant
Figure 1 (A) Left: endoscopic view of the transverse colon in Crohn’s disease (CD) revealing a cluster of deep ulcers. (B) Centre: magnetic
resonance enterography showing extensive terminal ileal disease. (C) Right: perianal disease (inﬂamed skin tag and external oriﬁce of a ﬁstula at
10:00) in CD patient (reproduced with permission).
Figure 2 Diagnostic pathways in Crohn’s disease (CD). Patients
displaying features, consistent with CD should be fast tracked for
specialist review. IBD, inﬂammatory bowel disease; MRE, magnetic
resonance enterography; VCE, video capsule endoscopy.
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hepatocellular liver disease is rare. Nausea and vomiting have
been reported in 11%–24% of patients, and can be successfully
controlled with antiemetic medication in many but not all
patients.38 Contraception is essential. Teaching patients and fam-
ilies to deliver the drug in the home setting is achievable for the
majority, allowing ﬂexibility in drug delivery, increasing drug
acceptability while reducing overall cost.39
Anti-TNFα antibodies
Prior to commencing anti-TNF therapy (chimeric monoclonal
antibody: inﬂiximab; or humanised monoclonal antibody: adali-
mumab), patients have to be screened for tuberculosis and hepa-
titis B to prevent reactivation. Varicella immunity should also be
established and in seronegative cases, and if feasible, varicella
zoster immunisation should be considered before treatment.
Anti-TNF treatment is recommended for inducing and main-
taining remission in children with steroid refractory disease or
CD affecting the gut lumen (luminal disease) despite optimised
immunomodulation. Anti-TNF therapy is also used by some
clinicians as primary induction therapy in active perianal disease
and in patients at risk of poor outcomes, but both indications
are currently outside of the drugs licence.7
In luminal disease, inﬂiximab response rates of up to 90%
and remission rates at 1 year of 55%–60% have been
reported.40 41 Inﬂiximab improved outcomes of perianal CD
with response rates of 75% and remission rates of 50% at
1 year.42 Adalimumab achieved 1-year remission rates of 45% in
anti-TNFα antibody naïve children and 20% in inﬂiximab
non-responders.43
Inﬂiximab is ﬁrst administered intravenously in doses of
5 mg/kg at weeks zero, two and six followed by 8-weekly infu-
sions. Adalimumab is administered subcutaneously on alternate
weeks (most commonly 40 mg) after initial loading dose(s) of
80 or 160 mg.
The proportion of primary anti-TNF non-responders (failure
to respond after induction course of 6 weeks) in paediatric CD
is low (10%–25%). However, more commonly antibody forma-
tion against the drug over time can result in secondary loss of
response.44 The formation of antibodies and the resulting loss
of response are reduced by the use of co-immunosuppression
with either thiopurines or MTX.33 45 As such the strategy of
combination therapy is commonly employed in the UK, but this
needs to be continuously balanced against the increased side
effect proﬁle of this strategy. Recently, inﬂiximab drug and anti-
body levels have become available to support decision making
in partial or complete lack/loss of treatment response.46 47 If
antibody and drug trough levels are inadequate, dose escalation
and/or interval reduction can regain response.7
Adverse effects following anti-TNF therapy include acute
infusion reactions (up to 15%), delayed hypersensitivity reac-
tions (8%), skin eruptions (eczema/psoriasis, 8%) and serious
infections (3.3%) including reactivation of latent tuberculosis.48
Other treatments
Inducing remission with aminosalicylates may be considered
rarely in mild colonic CD in a small subset of patients only. The
evidence for other immunomodulators is not as extensive as for
thiopurines and MTX, but thalidomide, sirolimus and tacroli-
mus can be useful in selected patients’ dependant on individual
circumstances.49–51
Surgery in CD
The risk of requiring surgery within 5 years of diagnosis in
paediatric CD is around 20%.52 In one retrospective study, out
of 69 patients who required surgery, 58% underwent right
hemi-colectomy, 3% subtotal colectomy, 12% stoma formation
and 14% surgery for perianal disease.53
Table 1 The weighted Paediatric Crohn’s Disease Activity Index16
Score
History (recall, 1 week)
Abdominal pain
0=none 10=mild: brief, does not interfere with activities 20=moderate/severe: daily, longer lasting, affects
activities, nocturnal
______
Patient functioning, general well-being
0=no limitation of activities, well 10=occasional difficulty in maintaining age appropriate
activities, below par
20=frequent limitation of activity, very poor ______
Stools (per day)
0=0–1 liquid stools, no blood 7.5=up to 2 semiformed with small blood, or 2–5 liquid 15=gross bleeding, or ≥6 liquid or nocturnal diarrhoea ______
Laboratory
Erythrocyte sedimentation rate
0≤20 mm/h 7.5=20–50 mm/h 15≥50 mm/h ______
Albumin
0≥3.5 g/dL 10=3.1–3.4 g/dL 20≤3.0 g/dL ______
Examination
Weight
0=weight gain or voluntary weight
stable/loss
5=involuntary weight stable, weight loss 1%–9% 10=weight loss ≥10% ______
Perianal disease
0=none, asymptomatic tags 7.5=1–2 indolent fistula, scant drainage, no tenderness 15=active fistula, drainage, tenderness or abscess ______
Extraintestinal manifestations
fever ≥38.5°C for 3 days over last week, definite arthritis, uveitis, erythema nodosum and pyoderma gangrenosum
0=none 10=one or more ______
Total score (0–125)
Remission <12.5; mild 12.5–40; moderate 40–57.5; severe disease activity >57.5.
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Patients with late-onset paediatric, severe/extensive or strictur-
ing/penetrating CD have increased the risk for bowel surgery.
Emergency surgical interventions are indicated in circumstances
such as severe haemorrhage, intestinal perforation and toxic
megacolon.
Otherwise, surgery is commonly carried out in three scen-
arios: isolated/localised disease including perianal disease, IBD
refractory to conventional medical therapy and when complica-
tions arise such as strictures and ﬁstulae.53 54 Resectional
surgery is increasingly being carried out laparoscopically.
In cases where CD is limited to an isolated bowel segment
(eg, ileocaecal CD), surgery might establish a postoperative
recurrence-free interval to allow for growth and development.55
Bowel rest through temporary diversion ileostomy has been
considered in patients with extensive colonic and/or perianal
disease refractory to medical treatment. Treatment of perianal
ﬁstulising CD with anti-TNF therapy is effective and signiﬁcantly
reduces the need for surgery.56 Combined medical and surgical
treatment within the MDT is regarded by many as the best treat-
ment approach to complex perianal disease.57 Enteroenteric ﬁs-
tulae may respond to anti-TNF therapy, but are more likely to
require surgical intervention. Perianal ﬁstulae can be transsphinc-
teric, intersphincteric, suprasphincteric, extrasphincteric or suba-
nodermal. Fistulae management requires an individualised
approach considering surgical and medical options. Surgical ﬁs-
tulotomy in patients with a simple, symptomatic ﬁstula is consid-
ered appropriate. Surgery in complex ﬁstulae bares a high risk of
sphincter damage and faecal incontinence.58 59 Insertion of
loose, ie non-cutting seton sutures after incision and drainage
can facilitate better long-term healing, and prevention of recur-
rence of abscesses in selected patients with perianal disease.59
Strictures particularly involving the terminal ileum/ileocaecal
valve are a common indication for CD surgery.52 Limited resec-
tions or stricturoplasty are considered best practice to preserve
gut length and prevent short bowel syndrome.
GENERAL CONSIDERATIONS
IBD and cancer
The overall risk to develop malignancies such as lymphomas for
children with IBD is low, but higher than the general paediatric
population. In one large cohort study of paediatric IBD patients,
two lymphomas were diagnosed in a 30-year period (the risk of
developing lymphoma on thiopurines was found to be approxi-
mately eightfold higher when compared with the general popu-
lation).60 Over 30 cases of hepatosplenic T-cell lymphoma,
which is associated with very high mortality and mainly affects
young men, have been reported in IBD patients. The majority
(56%) were treated with anti-TNF–thiopurine combination
therapy.61 Mortality overall is very rare in paediatric IBD and
usually is secondary to infection or cancer.62
Vaccination
Live vaccination (eg, varicella) should be considered in immune
competent IBD patients prior to long-term immunosuppression.
The annual inactivated inﬂuenza vaccination should be offered
to all children with IBD too.63
Education
Children and their parents should be encouraged to engage with
national and international patients’ IBD forums such as CICRA
(‘Crohn’s in Childhood Research Association’) (http://www.
cicra.org) and ‘Crohn’s and Colitis UK’ (http://www.
crohnsandcolitis.org.uk).
Multidisciplinary team
National standards dictate that children and young people with
IBD are managed, at least in part, by a Paediatric
Gastroenterology team including medical, nursing and dietetic
staff.64 65 In this age group, disease control and maintaining
patient engagement can be challenging and appropriate support
to the patient and carers is vital.
Transition
Transition to adult services is a particularly challenging time for
the patient and family. It is best done as a staged process over
months to years dependent on the physical, psychological and
emotional state of the young person and should prepare them for
managing their consultation independently.66 67 Continuity and
consistency are recommended to encourage engagement in tran-
sition, and the clinical nurse specialist working within the MDT
often fulﬁls this role in addition to coordinating the process.
Compliance
Non-adherence to medical therapies is common in chronic
disease management and can be further exacerbated during ado-
lescence.68 69 Knowledge of medication does not necessarily
equate to compliance and forgetting, lack of time, no perceived
beneﬁt and too many tablets are common themes in patients
with IBD and other conditions. Consultations with the child or
young person should focus on devising practical and realistic
management plans. ‘Safety netting’ (agreeing a clear plan for
what to do if symptoms do not resolve following treatment),70
can empower and support the young person in managing their
IBD.
CONCLUSION
The management of paediatric CD has evolved signiﬁcantly
over recent years with evidence-based guidelines now in place
to assist day-to-day practice. Novel tools for personalised IBD
management (drug metabolites, anti-TNF antibodies, stool
inﬂammatory markers) provide a better understanding of the
patients’ disease status. The pathophysiology of CD remains
relatively poorly understood, but advances in molecular tech-
nologies are likely to facilitate a deeper understanding of path-
ways involved in IBD pathogenesis, and will hopefully reveal
novel disease biomarkers and treatment strategies.
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